The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, vol.131, issue.6, pp.803-820, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Histological classification and molecular genetics of meningiomas, Lancet Neurol, vol.5, issue.12, pp.1045-1054, 2006. ,
Intracranial meningiomas of atypical (WHO grade II) histology, J Neurooncol, vol.99, issue.3, pp.393-405, 2010. ,
TERT Promoter mutations and risk of recurrence in meningioma, J Natl Cancer Inst, vol.108, issue.5, p.377, 2016. ,
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis, Lancet Oncol, vol.18, issue.5, pp.682-694, 2017. ,
EANO guidelines for the diagnosis and treatment of meningiomas, Lancet Oncol, vol.17, issue.9, pp.383-391, 2016. ,
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma, Neuro Oncol, vol.18, issue.5, pp.649-655, 2016. ,
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations, Nat Genet, vol.45, issue.3, pp.285-289, 2013. ,
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO, Science, vol.339, issue.6123, pp.1077-1080, 2013. ,
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations, Acta Neuropathol, vol.125, issue.3, pp.351-358, 2013. ,
Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas, Neuro Oncol, vol.18, issue.9, pp.1199-1208, 2016. ,
From the clinician's point of viewwhat is the status quo of positron emission tomography in patients with brain tumors?, Neuro Oncol, vol.17, issue.11, pp.1434-1444, 2015. ,
FDG PET/CT in oncology: "raising the bar, Clin Radiol, vol.65, issue.7, pp.522-535, 2010. ,
18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma, Eur J Nucl Med Mol Imaging, vol.36, issue.10, pp.1574-1582, 2009. ,
Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study, Radiology, vol.164, issue.2, pp.521-526, 1987. ,
Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET, J Nucl Med, vol.38, issue.1, pp.26-30, 1997. ,
Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from highgrade brain tumors with PET, Radiology, vol.195, issue.1, pp.47-52, 1995. ,
1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery, J Nucl Med, vol.51, issue.6, pp.883-891, 2010. ,
Expression of somatostatin receptor subtypes in human brain tumors, Int J Cancer, vol.76, issue.5, pp.620-627, 1998. ,
High incidence of somatostatin receptors in human meningiomas: biochemical characterization, J Clin Endocrinol Metab, vol.63, issue.2, pp.433-438, 1986. ,
Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen, Acta Neuropathol, vol.130, issue.3, pp.441-443, 2015. ,
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature, Future Oncol, vol.10, issue.14, pp.2259-2277, 2014. ,
Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue, J Nucl Med, vol.56, issue.3, pp.347-353, 2015. ,
Detection of cranial meningiomas: comparison of 68 Ga-DOTATOC PET/CT and contrast-enhanced MRI, Eur J Nucl Med Mol Imaging, vol.39, issue.9, pp.1409-1415, 2012. ,
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas, J Nucl Med, vol.42, issue.7, pp.1053-1056, 2001. ,
Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice, PLoS One, vol.9, issue.11, p.111624, 2014. ,
Procedure guidelines for PET/ CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, Eur J Nucl Med Mol Imaging, vol.37, issue.10, pp.2004-2010, 2010. ,
MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?, Eur J Nucl Med Mol Imaging, vol.39, issue.6, pp.1021-1029, 2012. ,
The clinical value of PET with amino acid tracers for gliomas WHO grade II, Int J Mol Imaging, p.372509, 2011. ,
Role of O-(2-18F-fluoroethyl)-Ltyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma, J Nucl Med, vol.54, issue.12, pp.2046-2054, 2013. ,
Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas, Int J Radiat Oncol Biol Phys, vol.72, issue.4, pp.1161-1167, 2008. ,
Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results, Eur J Nucl Med Mol Imaging, vol.42, issue.3, pp.459-467, 2015. ,
Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG PET, Eur J Nucl Med Mol Imaging, vol.29, issue.2, pp.176-182, 2002. ,
Clinical characteristics of meningiomas assessed by 11 C-methionine and 18 F-fluorodeoxyglucose positronemission tomography, J Neurooncol, vol.107, issue.2, pp.379-386, 2012. ,
68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate?, Neuro Oncol, vol.18, issue.7, pp.1021-1027, 2016. ,
Positron emission tomography imaging of meningioma in clinical practice: review of literature and future directions, Neurosurgery, vol.70, issue.4, pp.1033-1041, 2012. ,
Boron neutron capture therapy for recurrent high-grade meningiomas, J Neurosurg, vol.119, issue.4, pp.837-844, 2013. ,
Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas, Neuro Oncol, vol.11, issue.4, pp.430-436, 2009. ,
Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates, Urol Oncol, vol.31, issue.4, pp.427-435, 2013. ,
Current use of PSMA-PET in prostate cancer management, Nat Rev Urol, vol.13, issue.4, pp.226-235, 2016. ,
C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience, Clin Nucl Med, vol.34, issue.1, pp.7-10, 2009. ,
Diagnosis of complex renal cystic masses and solid renal lesions using PET imaging: comparison of 11C-acetate and 18F-FDG PET imaging, Clin Nucl Med, vol.39, issue.3, pp.208-214, 2014. ,
Kinetic analysis of dynamic (11)C-acetate PET/CT imaging as a potential method for differentiation of hepatocellular carcinoma and benign liver lesions, Theranostics, vol.5, issue.4, pp.371-377, 2015. ,
Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature, BJU Int, vol.112, issue.8, pp.1062-1072, 2013. ,
11C-acetate PET imaging of prostate cancer, J Nucl Med, vol.43, issue.2, pp.181-186, 2002. ,
Multimodal approach to detect osseous involvement in meningioma: additional value of (18)F-fluoride PET/CT for conventional imaging, Radiology, vol.273, issue.2, pp.521-528, 2014. ,
18F-fluoride PET/CT allows detection of hyperostosis and osseous involvement in meningioma: initial experience, Clin Nucl Med, vol.38, issue.3, pp.125-131, 2013. ,
Sphenoid wing meningioma behavior on 11C-PiB and 18F-FDG PET, Clin Nucl Med, vol.40, issue.1, pp.81-82, 2015. ,
Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand PET/CT, Clin Nucl Med, vol.41, issue.12, pp.956-958, 2016. ,
The incidental suggestive meningioma presenting as high 18F FP-CIT uptake on PET/CT study, Clin Nucl Med, vol.39, issue.1, pp.97-98, 2014. ,
, Lancet, vol.363, issue.9420, pp.1535-1543, 2004.
Dural lesions mimicking meningiomas, Hum Pathol, vol.33, issue.12, pp.1211-1226, 2002. ,
Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway, Orbit, vol.34, issue.1, pp.16-22, 2015. ,
Glucose and methionine uptake and proliferative activity in meningiomas, Neurol Res, vol.21, issue.7, pp.640-644, 1999. ,
Analysis of progression and recurrence of meningioma using (11)C-methionine PET, Ann Nucl Med, vol.27, issue.8, pp.772-780, 2013. ,
Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET, Int J Radiat Oncol Biol Phys, vol.65, issue.1, pp.222-227, 2006. ,
Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas, Eur J Nucl Med Mol Imaging, vol.37, issue.2, pp.310-318, 2010. ,
PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report, J Nucl Med, vol.48, issue.5, pp.720-725, 2007. ,
11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy, Int J Radiat Oncol Biol Phys, vol.66, issue.2, pp.339-344, 2006. ,
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review, J Neurosurg, vol.122, issue.1, pp.4-23, 2015. ,
Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET-CT compared to contrast-enhanced MRI, J Nucl Med, 2017. ,
Orbit-associated tumors: navigation and control of resection using intraoperative computed tomography, J Neurosurg, vol.124, issue.5, pp.1319-1327, 2016. ,
Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience, Int J Radiat Oncol Biol Phys, vol.56, issue.5, pp.1450-1463, 2003. ,
DOTATOC-PET/CT for meningioma IMRT treatment planning, Radiat Oncol, vol.68, p.56, 2009. ,
Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy, Int J Radiat Oncol Biol Phys, vol.85, issue.1, pp.68-73, 2013. ,
Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methionine PET, Eur J Nucl Med, vol.27, issue.12, pp.1793-1799, 2000. ,
Long-term evaluation of the effect of hypofractionated highenergy proton treatment of benign meningiomas by means of (11)C-Lmethionine positron emission tomography, Eur J Nucl Med Mol Imaging, vol.43, issue.8, pp.1432-1443, 2016. ,
Radiopeptides for imaging and therapy: a radiant future, J Nucl Med, vol.56, issue.12, pp.1809-1812, 2015. ,
Yttrium-90 DOTATOC: first clinical results, Eur J Nucl Med, vol.26, issue.11, pp.1439-1447, 1999. ,
Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma, Eur J Nucl Med Mol Imaging, vol.36, issue.9, pp.1407-1416, 2009. ,
Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature, Cancer Biother Radiopharm, vol.29, issue.5, pp.193-199, 2014. ,
Somatostatin receptortargeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial, J Nucl Med, vol.56, issue.2, pp.171-176, 2015. ,
90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas, J Nucl Med, vol.56, issue.11, pp.1748-1751, 2015. ,
Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma, Radiat Oncol, vol.7, p.99, 2012. ,
Successful radiopeptide targeting of metastatic anaplastic meningioma: case report, Radiat Oncol, vol.6, p.94, 2011. ,
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma, J Nucl Med, vol.47, issue.10, pp.1599-1606, 2006. ,
Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake, Neuro Oncol, vol.18, issue.11, pp.1538-1547, 2016. ,
²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience, Eur J Nucl Med Mol Imaging, vol.41, issue.11, pp.2106-2119, 2014. ,
Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study, Eur J Nucl Med Mol Imaging, vol.29, issue.4, pp.486-493, 2002. ,